Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $14.30, but opened at $12.59. Mineralys Therapeutics shares last traded at $13.25, with a volume of 2,172,308 shares traded.
Analysts Set New Price Targets
Several equities analysts recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Monday, March 10th. The Goldman Sachs Group dropped their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Guggenheim reissued a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.
Get Our Latest Stock Analysis on MLYS
Mineralys Therapeutics Stock Performance
The stock's 50-day moving average is $10.42 and its 200 day moving average is $11.93. The stock has a market capitalization of $710.16 million, a PE ratio of -3.91 and a beta of 1.50.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. Analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.
Insider Activity at Mineralys Therapeutics
In related news, CEO Jon Congleton sold 18,333 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.06, for a total value of $166,096.98. Following the completion of the sale, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. This represents a 2.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company's stock, valued at approximately $2,057,482.70. This represents a 4.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 33.24% of the company's stock.
Hedge Funds Weigh In On Mineralys Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Mineralys Therapeutics during the 4th quarter worth approximately $48,000. ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. grew its position in Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock valued at $130,000 after buying an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Mineralys Therapeutics in the 4th quarter valued at $145,000. Finally, PDT Partners LLC acquired a new position in Mineralys Therapeutics in the 3rd quarter valued at $148,000. Institutional investors and hedge funds own 84.46% of the company's stock.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.